Leerink Partnrs Has Negative Estimate for IONS Q1 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Analysts at Leerink Partnrs lowered their Q1 2025 earnings estimates for Ionis Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.21) per share for the quarter, down from their previous forecast of ($1.18). The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($3.60) EPS, FY2026 earnings at ($2.67) EPS and FY2027 earnings at ($1.31) EPS.

Other research analysts have also issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a research note on Tuesday. Citigroup dropped their price objective on Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. Guggenheim restated a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Thursday, April 3rd. Redburn Atlantic assumed coverage on Ionis Pharmaceuticals in a research report on Monday, March 31st. They issued a “neutral” rating and a $39.00 price target on the stock. Finally, BMO Capital Markets reduced their price objective on Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating for the company in a research report on Thursday, February 20th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $56.72.

Ionis Pharmaceuticals Trading Up 0.2 %

NASDAQ:IONS opened at $28.40 on Friday. The company’s 50 day moving average is $30.86 and its 200-day moving average is $34.24. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. Ionis Pharmaceuticals has a 12 month low of $23.95 and a 12 month high of $52.34. The firm has a market cap of $4.51 billion, a price-to-earnings ratio of -9.34 and a beta of 0.29.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The business had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. During the same quarter in the prior year, the firm posted $0.12 EPS. The firm’s revenue for the quarter was down 30.2% on a year-over-year basis.

Institutional Trading of Ionis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Capital World Investors boosted its holdings in shares of Ionis Pharmaceuticals by 46.5% in the 4th quarter. Capital World Investors now owns 11,465,413 shares of the company’s stock worth $400,831,000 after acquiring an additional 3,637,041 shares in the last quarter. Norges Bank bought a new stake in shares of Ionis Pharmaceuticals during the fourth quarter worth $59,948,000. Vanguard Group Inc. increased its stake in shares of Ionis Pharmaceuticals by 9.4% in the fourth quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company’s stock valued at $575,880,000 after buying an additional 1,416,781 shares in the last quarter. Vestal Point Capital LP bought a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at about $20,801,000. Finally, Orbimed Advisors LLC lifted its position in Ionis Pharmaceuticals by 21.2% during the 4th quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company’s stock worth $98,494,000 after buying an additional 492,900 shares in the last quarter. 93.86% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Patrick R. O’neil sold 1,207 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $32.35, for a total value of $39,046.45. Following the sale, the executive vice president now owns 56,245 shares in the company, valued at approximately $1,819,525.75. The trade was a 2.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Brett P. Monia sold 38,843 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $31.65, for a total transaction of $1,229,380.95. Following the sale, the chief executive officer now owns 180,683 shares of the company’s stock, valued at $5,718,616.95. This trade represents a 17.69 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 63,167 shares of company stock worth $2,010,458. Company insiders own 2.71% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.